CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...

U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Our school teaching resources make it easy to teach and learn about dementia from Key Stage 1 to Key Stage 4. No prior knowledge of dementia is required. All of these resources can be used in class, ...

There is no strong evidence to suggest that everyday contact with metals increases a person’s risk of developing dementia. Metal atoms such as copper, zinc and iron are naturally present in the human ...

Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...